-
Regulatory Approval and Economic Evaluation of Tumor-Agnostic Therapies: A Comparative Study of Larotrectinib and Entrectinib
Sep 9, 2025, 16:22 PM -
Trends and Scope of Japan’s Across-the-Board Pharmaceutical Price Revisions in FY2021-25
Sep 9, 2025, 16:22 PM -
Calibrating Large Language Model Probabilities to Achieve Target Recall in Systematic Review Screening
Sep 9, 2025, 16:22 PM -
What Characteristics Are Associated With Having a Work Limitation Among United States Adults With Asthma?
Sep 9, 2025, 16:22 PM -
Health Utilities Among Patients With Chronic Rhinosinusitis With Nasal Polyps: An Exploratory Analysis From the WAYPOINT Trial
Sep 9, 2025, 16:22 PM -
Exploring Knowledge Attitudes and Perspectives on Respiratory Viruses Vaccination Among Older Adults in the US
Sep 9, 2025, 16:22 PM -
Comparative Efficacy and Safety of Avacincaptad Pegol vs. Pegcetacoplan in Treatment of Geographic Atrophy: Insights From a Multilevel Network Meta-Regression
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Composite Materials for Hard Dental Tissue Defect Restorations From Budget Financing in Wartime in Ukraine
Sep 9, 2025, 16:22 PM -
Accessibility and Time to Reimbursement of Treatments With Substantial Benefit: A Comparative Analysis Focused on Inequalities Between Different European Countries and Different Tumor Types
Sep 9, 2025, 16:22 PM -
Drivers of Inpatient Costs in Oncology Patients Undergoing Major Abdominal Surgery: Evidence from a Middle-Income Country
Sep 9, 2025, 16:22 PM -
Recognizing the Full Value of Novel Antibiotics: Identifying Value Elements in the Context of Antimicrobial Resistance
Sep 9, 2025, 16:22 PM -
Economic Evaluations Cost and Resource Utilization in Early Triple-Negative and Low Hormone Receptor-Positive Breast Cancer: A Comprehensive Systematic Review
Sep 9, 2025, 16:22 PM -
From Development to Reimbursement Evidence-Generation Strategies for HealthTech in Europe
Sep 9, 2025, 16:22 PM -
A Review of Approaches to Select Instruments and Items to Measure Patient Reported Tolerability in Clinical Trials in Oncology
Sep 9, 2025, 16:22 PM -
Prices And Reimbursement Conditions for Poly (ADP-RIBOSE) Polymerase Inhibitors (PARPi) Indicated for Ovarian Cancer in Spain
Sep 9, 2025, 16:22 PM -
The Association of Glucagon-Like Peptide-1 Receptor Agonists With Hepatopancreatobiliary Diseases in Individuals With Type 2 Diabetes Mellitus
Sep 9, 2025, 16:22 PM -
The Estimation of Utility Weights From the Rett Syndrome Behavior Questionnaire
Sep 9, 2025, 16:22 PM -
Publicly Funded Fertility Preservation Services for Medical Reasons in Selected Countries
Sep 9, 2025, 16:22 PM -
Implementing Coverage With Evidence Development for Medicines With Uncertain Clinical Benefit: Insights From the Netherlands
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Assessment of Orphan Drugs in France: Key Insights from CEESP Reviews (2021-2024)
Sep 9, 2025, 16:22 PM
